GlaxoSmithKline plc (GLAXF)
| Previous close | 19.85 |
| Open | 19.85 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 19.85 - 19.85 |
| 52-week range | 16.65 - 22.12 |
| Volume | |
| Avg. volume | 1,314 |
| Market cap | 83.31B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 13.41 |
| EPS (TTM) | 1.48 |
| Earnings date | N/A |
| Forward dividend & yield | 0.80 (4.04%) |
| Ex-dividend date | 22 Feb 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 2-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ZacksGSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
